ABSTRACT: Cyclooxygenase (COX) is the rate-limiting enzyme in the production of prostaglandins. COX-2, the predominant COX isoform in brain, is induced by synaptic activity. COX-2-generated prostaglandins are important regulators for a range of activities under physiologic conditions. However, under pathologic conditions, COX-2 activity can produce reactive oxygen species and toxic prostaglandin metabolites that can exacerbate brain injury. In this study, we examine the developmental production of COX-2 and test the ability of a COX-2 inhibitor, SC58125, to attenuate traumatic brain injury in developing rats. We show that constitutive COX-2 concentration is low (0.5-fold adult concentration) during the first postnatal week and then increases to 3-fold of adult levels between days 14 -60. Controlled cortical impact (CCI) at postnatal day (PND) 17, but not PND 7, caused an additional 3-fold increase in COX-2 content and was associated with an increase in the COX-2 product PGE 2 . Treatment with the COX-2 inhibitor SC58125 in PND17 rats exposed to CCI attenuated the rise in PGE 2 but did not attenuate lesion volume or improve performance in the Morris water maze. C OX is the rate-limiting enzyme in the production of prostaglandins from arachidonic acid. There are two COX isoforms, COX-1 and COX-2. COX-1 is a constitutive isoform produced in many tissues including stomach, kidneys, blood vessels, and platelets. COX-2 is an inducible isoform found in inflammatory cells and brain; it is the predominant isoform in brain. In brain, COX-2 is induced by synaptic activity and COX-2-generated prostaglandins are important physiologic regulators for a range of activities including local cerebral blood flow and learning. The recent controversy surrounding the association of stroke and COX-2 inhibitors in otherwise healthy patients reinforces the notion that COX-2 has an important role in cerebrovascular homeostasis. On the other hand, overexpression of COX-2 can be harmful. Under pathologic conditions including trauma, ischemia, and chronic neurodegenerative conditions, COX-2 activity is up-regulated, producing reactive oxygen species and toxic prostaglandin metabolites that worsen injury [reviewed in (1)]. Accordingly, experimental models of ischemic brain injury show less damage in rodents treated with COX-2 inhibitors and in COX-2 knock out mice.
C
OX is the rate-limiting enzyme in the production of prostaglandins from arachidonic acid. There are two COX isoforms, COX-1 and COX-2. COX-1 is a constitutive isoform produced in many tissues including stomach, kidneys, blood vessels, and platelets. COX-2 is an inducible isoform found in inflammatory cells and brain; it is the predominant isoform in brain. In brain, COX-2 is induced by synaptic activity and COX-2-generated prostaglandins are important physiologic regulators for a range of activities including local cerebral blood flow and learning. The recent controversy surrounding the association of stroke and COX-2 inhibitors in otherwise healthy patients reinforces the notion that COX-2 has an important role in cerebrovascular homeostasis. On the other hand, overexpression of COX-2 can be harmful. Under pathologic conditions including trauma, ischemia, and chronic neurodegenerative conditions, COX-2 activity is up-regulated, producing reactive oxygen species and toxic prostaglandin metabolites that worsen injury [reviewed in (1) ]. Accordingly, experimental models of ischemic brain injury show less damage in rodents treated with COX-2 inhibitors and in COX-2 knock out mice.
Both COX-1 (2) and COX-2 are increased after traumatic brain injury (3) (4) (5) . However, treatment using COX-2 inhibitors in models of traumatic brain injury have led to contradictory results, with some showing a benefit to therapy (6 -9) and others showing harm or no benefit (3, 10) .
COX-2 in the immature brain is developmentally regulated. In the rodent, there is very little COX-2 expression immediately after birth. Expression then increases to achieve peak values during the third and fourth postnatal weeks before decreasing to the intermediate levels contained in adult brain (11, 12) . A similar pattern of expression is found for nitric oxide synthase (NOS). NOS, like COX, is an important modulator of neuronal function under physiologic conditions and is a paradoxically toxic molecule under pathologic conditions. The expression pattern of COX and NOS, with a peak at approximately 1 mo, parallels cortical maturation and synaptogenesis, suggesting that they are potentially important regulators of normal neuronal development. Indeed, abnormal distribution of COX-2 has been described in human children with the neurodegenerative disease Rett syndrome (11) . On the other hand, NOS and COX-2 have been shown to act synergistically to worsen ischemic brain injury (13) . Thus, under pathologic conditions, the combined peak of COX-2 and NOS expression in maturing brain can create a pathobiologic milieu that may exacerbate brain injury.
The effect of TBI upon COX-2 expression in developing brain and the use of COX-2 inhibition as treatment for TBI in developing animals have not been investigated. In this study, we examine the effects of TBI upon rats before and during peak constitutive COX-2 expression (PND 7 and PND17, respectively). We confirm that COX-2 expression is negligible in the newly born rat and peaks at 3-4 wk. We show that COX-2 is induced by TBI in PND 17 but not PND 7 rats. Finally, we compare prostaglandin production, lesion size, and Sample sizes and statistical analysis. A total of 128 rats were used. Four rats per age group were used for Western blots of constitutive COX-2 in naïve, developing rats (total 28). Eleven injured and 8 control rats were used for Western blots of induced COX-2. Two to three rats per group were used for immunohistochemistry (total 10). Two to five rats per time point in each group were used for prostaglandin PGE 2 assay (total 36). Brain weight, lesion size, and MWM performance were performed on the same cohort of rats using 5-10 per group (total 35). ANOVA was used for between group comparisons with ROD, prostaglandin ELISA, lesion size, and brain weight. Tukey post hoc analysis was used for subgroup comparisons. Repeated measures analysis was used for MWM score, body weight, and temperature.
RESULTS

COX-2 expression.
Western blot analysis of whole brain homogenates from naïve rats shows constitutive COX-2 is increased 2-3-fold in rats from 14 to 30 d compared with very young (PND Յ7) or mature (PND 90) rats (Fig. 1) . Western blot analysis from ipsilateral and contralateral hemispheres at 24 h in rats injured with CCI show a significant increase in COX-2 in the ipsilateral hemisphere of PND 17 rats (p ϭ 0.03 post hoc testing with naïve and sham rats pooled as control) but not PND 7 rats (Fig. 2) . ROD of injured PND 17 was greater than injured PND 7 (p ϭ 0.001). Figure 3 shows representative COX-2 immunohistochemistry. Although the amount of tissue loss is severe in both PND 7 and PND 17 rats, only the PND 17 rats show increased COX-2 staining compared with naïve rats. Staining is most pronounced in cell bodies of the hippocampus, retrosplenial cortex, perilesional cortex, and lateral cortex. PGE 2 content. After determining that PND 17 rats had robust expression of COX-2 that was further increased after CCI, the activity of COX-2 was confirmed by measurement of the COX-2 product Prostaglandin E 2 (PGE 2 ) in PND 17 rats (Fig. 4) . ANOVA revealed significant effects of group (p ϭ 0.002) and sacrifice time (p ϭ 0.021). The interaction between group and sacrifice time was not significant. PGE 2 was increased approximately 4-fold at 24 h in rats with CCI compared with sham-controls. Oral administration of the COX-2 inhibitor SC58125 at 15 min and 24 h after CCI attenuated the increase PGE 2 measured at 24 and 48 h (statistically significant only at 48 h; p ϭ 0.008). Thus, SC58125 was pharmacologically effective within the CNS during the period of maximal COX-2 activity, as measured by PGE 2 .
Blockade of COX-2 activity. After determining that COX-2 activity could be attenuated with SC58125 treatment following CCI in PND17 rats, the effect of SC58125 treatment upon lesion size and cognitive deficit was assessed. Control groups included naïve rats, sham CCI (anesthetic, craniotomy, no CCI), and CCI ϩ methylcellulose (vehicle for SC58125). Rats were recovered for 10 d before MWM testing. They were killed for measurement of lesion size upon completion of MWM testing at PND 45. Temperature was measured at injury and at 4, 7, 24, and 31 h post injury. No rats developed fever (Tmax ϭ 37.8 C) and there was no effect of SC58125 upon temperature. Rats were weighed daily; there was no effect of SC58125 upon weight gain. Wet brain weight did not differ between groups at sacrifice (Table 1) . Similarly, the size of the lesion was not attenuated by SC58125 treatment (Table 1) .
MWM performance. MWM testing during the first 5 d (with hidden platform) showed that CCI ϩ SC58125 had improved performance compared with CCI rats, but not CCI ϩ vehicle rats, on d 2 and 3 (ANOVA p Ͻ 0.05) (Fig. 5) . In any Immunohistochemistry at 24 h of PND 17 CCI (middle) and PND 17 Naïve (bottom) from brain regions as labeled in the top panel. CCI rats showed increased staining in retrosplenial cortex (region 1, note increased staining in ipsilateral vs contralateral cortex in this image); CA1 hippocampus (region 2, note cellular staining in higher magnification cut out); perilesional cortex (region 3); and lateral cortex (region 4) of PND 17 rats. There was minimal increased staining in PND 7 rats, mostly localized to the perilesional region (not shown). There was no staining in control sections treated with secondary antibody only or with primary antibody quenched with blocking peptide (not shown). 
DISCUSSION
This study confirms that constitutive expression of COX-2 is developmentally regulated (with peak expression occurring at the same time as peak synaptogenesis in the rat) and is the first to show that COX-2 induction in response to brain injury is also developmentally regulated. We found an increase in COX-2 expression in PND 17, but not PND 7 rats, following CCI. A similar result has been reported by Tocco et al. (12) using a model of kainate-induced seizures; kainate induced intense seizures in PND 7, 14, 21, 28 and 60 rats but COX-2 mRNA was increased only in rats aged Ͼ PND 7. Both studies highlight the importance of examining mechanisms of injury and testing neuroprotective strategies across a spectrum of ages.
Developmental susceptibility to injury is likely related to the physiology of brain maturation including proliferation, migration, differentiation, synaptogenesis, myelination, and apoptosis. With respect to these events, the PND 7 rat has a relative developmental age of a newly born full-term human and the PND 17 rat has a relative developmental age of a toddler (PND 35-45 is adolescence). At the cellular level, pathways involved in programmed cell death, including caspase activation and classic apoptotic morphology, are relatively more active and more easily induced in very young (PND Յ7 rats) compared with older maturing or adult rats.
Maturation of excitatory neurotransmitter receptors (function, density, and distribution) peaks slightly later (PND 14 -21) and is associated with increased susceptibility to hypoxicischemic injury (15, 16) . The maturation of excitatory neurotransmitter receptors coincides with a peak in constitutive expression of both COX-2 (11,12) and NOS. COX and NOS have been shown to act synergistically to contribute to brain injury after cerebral ischemia (13) . NOS has previously been reported to increase following TBI in immature rats (17) . This is the first report of COX-2 induction following TBI in an immature animal.
There are several potential mechanisms whereby COX-2 might exacerbate neuronal injury. COX-2 converts arachidonic acid to PGH 2 via a cyclooxygenase followed by a peroxidase conversion that can generate free radicals (18) and exacerbate reperfusion injury (13) . PGH 2 is then metabolized by specific prostaglandin synthases into the first-order prostaglandins PGA 2 , PGD 2 , PGE 2 , PGI 2 , and thromboxane. The role of specific prostaglandins in brain injury is complicated by the diversity and distribution of prostaglandin receptors. Accordingly, some studies show prostaglandin-specific neurotoxic effects (19 -21) whereas others show neuroprotective effects (22) (23) (24) . This is further complicated by changes in the distribution of specific prostaglandin synthases during brain maturation (25) . Recently, a series of nonenzymatic metabolites of prostaglandins (cyclopentenone prostaglandins) have been shown to trigger neuronal apoptosis (26, 27) and perturb ubiquitin-dependent protein processing (28) . Cyclopentenone derivatives of PGD 2 have been reported following TBI (4). Thus, there are several potential mechanisms of COX-2 toxicity that could be relevant to TBI.
Although we found a robust increase in COX-2 following CCI in PND17 rats and there are biologically plausible reasons, as well as some experimental data, invoking a detrimental role for COX-2 in TBI, we found no protection using the COX-2 inhibitor SC58125. Our results are consistent with those reported by Dash et al. (3) and Koyfman et al. (10) but are in opposition to those reported by Cernak et al. (7), Gopez et al. (9) , and Moochhala et al. (8) . These disparate results might be caused by differences in models (CCI, fluidpercussion, and weight drop), treatment protocols (pre-or postinjury initiation of drugs, duration of therapy), specificity of drugs (e.g., Moochhala administered a combined NOS and COX-2 inhibitor), and outcome measures (duration of follow up, histology techniques, motor or cognitive functional tests). Table 2 compares these variables across studies: no clear pattern emerges that would explain the difference between the "positive" and "negative" studies. 
Table 1. Wet brain weight and lesion size (as measured by the ratio of left to right hemisphere through the impact site) in PND 17 rats at sacrifice (PND 45)
Naïve ϩ SC58125 (n ϭ 5) 
274
A strength of this study is that we used a clinically relevant postinjury treatment design and confirmed that the inhibitor had a pharmacologic effect in brain. We used PGE 2 content as a surrogate marker for COX-2 activity. We chose to measure PGE 2 based upon our previous success with the PGE 2 ELISA in a variety of experimental paradigms. PGD 2 and PGE 2 are the predominant prostaglandins in brain. We assume, but did not confirm, that changes in PGE 2 reflect changes in other members of the prostaglandin family. We chose a short duration of therapy (24 h) and confirmed that PGE 2 did not "rebound" at 48 h (24 h post dosing). The duration of COX-2 inhibition is an important consideration because there is data in rat models of inflammation showing that the prostaglandin response evolves over time from an early pro-inflammatory to a delayed anti-inflammatory (reparatory) phase and thus a short duration of therapy targets the early pro-inflammatory response. Whether or not a similar change from prostaglandinmediated inflammation to repair occurs following TBI has not been studied. We looked at PGE 2 content at 72 h and 7 d following CCI to determine the duration of trauma-mediated COX-2 activity. We found that PGE 2 was slightly elevated at both time points but the difference was not statistically different. This is consistent with the early (24 h) peak of PGE 2 reported in other models of TBI (8, 9) . However, the prolonged increase in COX-2 mRNA (3 d) and COX-2 immunohistochemistry (7 d) reported by others (5) suggests that COX-2 activity remains elevated, but below the threshold of our PGE 2 ELISA. Thus, COX-2 may continue to have effects at the cellular level beyond the duration of inhibition provided by the 24 h dose of NS58125.
Unlike Gopez et al. (9) , but like Dash and co-workers (3), we found no difference in MWM performance in treated rats. This may be due to differences in the scoring system used to assess maze performance. Alternatively, COX-2 might be particularly important during synaptogenesis in the rat and inhibition in the PND17 rat might interfere with development of normal connectivity. Along these lines, Kaufmann et al. (11) describe COX-2 immunoreactivity expression in a developmental pattern that parallels the crucial period for somatosensory and visual cortex development in the rat. They also demonstrate that COX-2 immunoreactivity is altered in patients with Rhett syndrome, a syndrome characterized by mental retardation, neurodegeneration, and altered dendritic maturation. Also, Teather et al. (29) describe impaired memory consolidation in rats treated with COX-2 inhibition during MWM training. Finally, COX-2 over expressing transgenic mice develop an age-dependent deficit in spatial memory (30) . Thus, chronic COX-2 inhibition or acute COX-2 inhibition immediately before a memory task might impair performance. It is less likely that a short course of COX-2 inhibition administered many days before testing, as occurred in this protocol, would have similar effects. On the other hand, there is evidence that even very brief inhibition of excitatory neurotransmitters in immature rats (e.g. a single dose of the NMDA inhibitor MK801 in PND 7 rats) can trigger diffuse apoptosis. Additional studies are needed to determine whether maturing PND17 rats are especially susceptible to memory impairment caused by COX-2 inhibition.
One limitation of this study is that we did not measure products of arachidonic acid that are unrelated to COX-2 activity. Specifically, COX-2 inhibition may shunt arachidonic acid metabolism into the lipoxygenase pathway that generates HETES and leukotrienes. Some of these lipoxygenase derivatives are neurotoxic while others are protective. A study by Gopez et al. (9) found that DFU treatment attenuated the increase in HETE while amplifying the production of EET following TBI (the authors speculate that this profile inhibits inflammation).
Another limitation of this study is that the tip diameter and depth of impact in the CCI device was greater for the PND 17 rats compared with the PND 7 rats. It was necessary to use a relatively larger force in the PND 17 rats to cause a similar amount of tissue loss. Tissue loss was substantial in both PND 7 and PND 17 rats (Fig. 3) . Because both paradigms resulted in similar tissue injury, the absence of COX-2 induction in the PND 7 rat was unlikely to be due to the differences in applied forces. Also, we did not see a difference in lesion size or brain weight in PND 17 rats treated with SC58125. It is possible that a more sensitive and robust assay of lesion size (stereometric volume measurement) might detect a difference, but, to date, no studies of COX-2 inhibition following TBI have reported a tissue sparing effect.
In summary, this is the first study to report that COX-2 induction following TBI is developmentally regulated. We were unable to show a neuroprotective effect of COX-2 inhibition. There are several potential explanations for the lack of neuroprotection in this study. Specifically, the lesion might be too severe to be manipulable, the inhibition protocol might be insufficiently protective, the chosen outcomes might be insensitive to small beneficial effects, or the developmental requirement of COX-2 for normal development might outweigh the pathologic contribution.
